Protoflavones, a rare group of natural flavonoids with a non-aromatic B-ring, are best known of their antitumor properties. The protoflavone B-ring is a versatile moiety that may be explored for other pharmacological purposes, but common cytotoxicity of these compounds is a limitation to such efforts. Protoapigenone was previously found to be active against the lytic cycle of Epstein-Barr virus (EBV). Further, the 5-hydroxyflavone moiety is a known pharmacophore against HIV-integrase. The aim of this work was to prepare a series of less cytotoxic protoflavone analogs, and to study their antiviral activity against HIV and EBV. Twenty-seven compounds including 18 new derivatives were prepared from apigenin through oxidative de-aromatization and subsequent continuous-flow hydrogenation, deuteration, and/or 4′-oxime formation. One compound was active against HIV at the micromolar range, and 3 compounds showed significant activity against the EBV lytic cycle at the medium-low nanomolar range. Among these, protoapigenone 1′-O-isopropyl ether (6) was identified as a promising lead due to its 73-times selectivity of its antiviral over its cytotoxic effect, which exceeds that of protoapigenone by 2.4-times. Our results open new opportunities to design new, potent and safe anti-EBV agents based on the natural protoflavone moiety.
Introduction
Protoflavonoids represent a relatively rare, naturally occurring group among natural flavonoids, possessing a non-aromatic B-ring and a hydroxyl function at C-1'. This unique structural moiety can appear in various forms, it is most typically a symmetric p-quinol dienone that may be partially or fully saturated, as shown by the examples of some natural protoflavones in Figure 1 [1] .
Many protoflavones are known for their potent anticancer activity, and until now, this bioactivity of this compound family is by far the most deeply investigated. Protoflavones are known apigenin was achieved by a hypervalent iodine reagent, [bis(trifluoroacetoxy)iodo]benzene, and the solvent was 10% v/v of water or alcohol in acetonitrile depending on the substituent to be coupled at C-1'. This allowed us to obtain compounds 2-8 as potential intermediates for further transformations, among which 6 was already a compound of interest for this study due to its very weak cytotoxicity as compared to the others.
As detailed above, the function dominantly responsible for the cytotoxicity of protoflavones is the symmetric dienone moiety on the B-ring, conferring pro-oxidant and Micheal-acceptor properties to the compound. Considering this, we employed two different targeted synthetic strategies to eliminate cytotoxicity: i) saturation of the double bonds through hydrogenation or deuteration, and ii) substituting the 4′-oxo group with an oxime function. Synthetic routes are shown in Scheme 1. Scheme 1. Semi-synthetic routes employed for the preparation of tetrahydro-, tetradeutero-or 4'oxime analogs of protoapigenone and its 1'-O-alkyl ether derivatives. Oxime derivatives 21-28 were obtained as racemates, however, for simplicity only one enantiomer is shown. Reaction conditions: a) CH3CN/ROH -9:1, PIFA (2 equiv.), 80°C, 1 h; b) H-Cube ® , 9-14: H2, 5% Pd/C or 15-20: D2, 5% Pd/BaSO4; c) NH2OH·HCl (3 equiv.), MeOH, reflux, 24 h; d) NH2OH·HCl (4 equiv.), MeOH, reflux, 3 h.
The hydrogenation of protoflavonoids' dienone moiety may result various products. Following our previously published procedure, saturation of the protoflavone B-ring was achieved with high selectivity under mild reaction conditions utilizing a modified H-cube ® continuous flow hydrogenation reactor [11] . As compared to traditional batch hydrogenation, employing this device has several advantages, i.e. the ease of handling of the explosive gas, precise control over the reaction conditions, instrumentally controlled gas pressure, sustainability and safe applicability. During this process, hydrogen gas was generated in situ in an electrolytic, high purity water fueled cell, from which it was forwarded to interact with the substrate's solution. The mixture was then passed through a stainless-steel tube filled with the catalyst, where the triphasic reaction took place. During each transformation, the catalyst bed was placed in a thermostat for the aim to retain the temperature. Products of the reactions were collected into glass vials and, following evaporation, RP-HPLC purification was applied to obtain tetrahydroprotoapigenone analogs 9-14 in high purity (Scheme 1).
Deuterium is applied in organic chemistry for several purposes. It is employed as a tracer in studies that aim to follow reaction routes or as a reference to determine the influence of isotope effects on the development of a reaction during kinetic studies. Isotope labeling is a technique with versatile continuously developing applications, that include pharmacological utilization via metabolomics as well. Importance of deuterium in isotope labeling is increasing as new applications emerge [15, 16] .
Deuterium can also be of potential interest in terms of drug discovery since it can significantly influence bioactivity of a compound due to the so-called isotope effect [17, 18] . Several methods are available for the synthetic preparation of deuterium containing compounds. The conventional batch synthesis of deuterated molecules suffers from similar drawbacks as hydrogenation, such as lack of sustainability and the low purity and high price of D2 gas. Therefore, in this current work, we used a previously established continuous flow method [19] [20] [21] , during which the required deuterium gas was generated from high purity D2O in situ with H-Cube ® . To ensure that no hydrogen-deuterium exchange occurs during the transformation, the reaction was performed in an aprotic solvent, ethyl acetate. For the same reason, we chose barium sulfate as the catalyst carrier, since activated charcoal might contain protic contaminations on its surface. In all other aspects of the synthesis, we followed the same procedure as in the case of hydrogenation, to obtain tetradeuteroprotoapigenone derivatives 15-20 (Scheme 1).
Several studies underline that the preparation of flavonoid oxime derivatives can be a simple yet effective synthetic option to enhance certain biological effects of the parent compound, e. g. antimicrobial [22] , antioxidant [23] , and antitumor [24] properties. To further increase chemical and consequential pharmacological diversity, compounds with different B-ring saturation and/or 1′-Osubstituents (6-9 and 14) were selected for the preparation of 4'-oximes (Scheme 1).
Our preliminary small-scale test reactions indicated that oxime formation of protoflavones is regioselective at the 4'-keto group, and under the synthetic conditions applied we did not observe the formation of 4-oxime nor 4,4'-dioxime side products. On the other hand, the solvent appeared to play a crucial role in the possible outcome of the transformation. Pyridine, ethanol and acetonitrile are probably among the most commonly used solvents in oxime synthesis. However, none of these worked in our case, and finally we found methanol as the best solvent for reacting protoflavones with hydroxylamine. Yields appeared to vary greatly depending on the substrate's concentration in the reaction solution, and we obtained the best yields with ca. 2-2.5 mg/mL concentrations; both lower and higher concentrations could significantly decrease efficiency of the transformation.
Regioselective transformation of the tetrahydroprotoflavone analogs 9 and 14 to their corresponding 4′-oximes 27 and 28 was straightforward. However, in case of protoflavones 6-8, each transformation was accompanied by a regioselective Michael addition of methanol at C-2', forming a methoxy group and saturating one of the double bonds to yield 2′-methoxy-2′3′dihydroprotoapigenone 4′-oxime derivatives 21-26. The orientation of the methoxy group was apparently random since the 1′,2′-cis and trans derivatives were formed in a ca. 1:1 ratio. When assigning the relative configuration of the 1′,2′-carbon atoms, we could not observe diagnostic NOESY cross-peaks between the 2′-methoxy and the 1′-O-alkyl substituents for any of these compounds. Therefore, cis-trans isomers were assigned based on the characteristic coupling constant patterns observed between H-2′ and H-3′a or H-3′b. To achieve this, structures were optimized by the MMFF94x force field in CCG-MOE, the H2′-C2′-C3′-H3′a and H2′-C2′-C3′-H3′b dihedral angles were measured, and theoretical 1 H-1 H 3 J coupling constants were calculated by means of the Bothner-By equation. The experimental coupling constants showed good agreements with the calculated values, unambiguously assigning compounds 21-23 as the 1′,2′-trans, and 24-26 as the 1′,2′-cis isomers. Nevertheless, while each compound was obtained as racemate, the newly formed oxime took a defined orientation in all of them. This suggests that the solvent addition took place to an intermediate of the reaction in a way that it determined the final orientation of the oxime. Since this way the exact data of the Δδ syn-anti parameters were not available, we considered compounds 27 and 28 as internal references, which provided us with the chemical shifts for both neighbouring methylenes of the oxime. In these compounds, C-3′ (syn) and C-5′ (anti) gave 13 C NMR chemical shifts at ca. 18.8 and 26.2 ppm, respectively. The 13 C NMR signals of the 3′-CH2 moieties of compounds 21-26 appeared within the range of 22.7-23.7 ppm, which, also taking into account the effect of the electron-rich neighbouring OCH3 group, strongly suggests that the oxime is present in E-orientation in each of these compounds.
Biological activities

Antiretroviral activity
Compounds 2, 6-14 and 21-28 were tested against HIV-1 using a pseudotype virus assay allowing only one cycle of viral replication and being more sensitive for compounds targeting the early steps of HIV replication such as reverse transcription and integration [25] . Tetrahydroprotoapigenone (9) was found to inhibit viral infection by ca. 50% at the non-cytotoxic concentration of 100 µM (see Supplementary Figure S55 ). While this represents a rather weak activity, it may still be of interest since this compound was not cytotoxic on the host cells at as high as 500 µM concentration.
Antiviral activity against EBV
Compounds 2 and 6-28 were tested for their activity on the EBV lytic cycle. To assess this, P3HR1 cells were treated with sodium butyrate and TPA for 24 h. As expected, lytic protein Rta was expressed after lytic induction. As a first screening, cells were treated with protoapigenone (2), used as a positive control, or compounds 6-28 at the induction of lytic cycle for 24 h. The concentration selected for screening was 0.25 µM, where protoapigenone (2) was previously found to exert a strong activity [10] . The results indicated that three of the analogs, 6, 7, and 8 can inhibit EBV lytic cycle at this concentration. These compounds were then tested for the dose dependency of their effect on the expression of Rta; results are shown in Figure 2 . (2) and its analogs 6-8. Cells were treated with the compounds at the time of lytic induction with SB and TPA. Cell lysates were harvested at 24 h after lytic induction. Proteins in the lysate were detected by immunoblotting using anti-Rta and anti--tubulin antibodies. Calculated IC50 values for 2, 6, 7 and 8 were 0.127, 0.467, 0.208, and 0.285 µM, respectively.
We found that, similarly to protoapigenone (2), compounds 6, 7 and 8 also caused a marked reduction in Rta levels at 0.50, 0.25, and 0.50 M, respectively, and the IC50 values were calculated as 0.467, 0.208, and 0.285 µM, respectively. The positive control protoapigenone (2) acted with an IC50 value of 0.127 µM that was in good agreement with our previous findings [10] . Subsequently, we conducted MTT assay to evaluate the cytotoxicity of these compounds to P3HR1 cells; results are shown in Figure 3 .
As expected from our previously published structure-activity relationship (SAR) study on the effect of 1′-O-alkyl substituents on the cytotoxic activity of protoflavones [7] , compounds 7 and 8 were similarly active as protoapigenone (2) , and the isopropyl-ether derivative 6 was much weaker in this regard. Selectivity of the anti-EBV vs. cytotoxic effect of these compounds, expressed as a ratio of the corresponding IC50 values, could therefore be calculated as follows: 2 (30.1), 6 (73.0), 7 (9.80), and 8 (17.3) . This means that compound 6 demonstrated a relevant, ca. 2.6-times increase in selectivity as compared to protoapigenone. It is also worth noting that by appropriate modifications of the Bring it was also found possible to shift the bioactivity profile of protoflavones to the other direction. Compound 7 was less effective against EBV and more cytotoxic than protoapigenone, i.e. ca. 3-times less selective in this regard. Therefore, SAR of protoflavonoids may be explored towards various therapeutic targets, and this is certainly a need to evaluate their real value concerning drug discovery. Figure 3 . Cytotoxicity of protoapigenone and its analogs to P3HR1 cells. Cells were cultured for 24 h in a medium containing protoapigenone (2) or compounds 6-8. Cell viability was evaluated by using MTT assay. Cells treated with 1% Triton X-100 (TX) were used as a positive control. The experiment was performed twice, and each sample involved in the experiment was prepared in duplicate. Error bars represent SD. Calculated IC50 values for compounds 2, 6, 7 and 8 were 3.86, 34.12, 2.04 and 4.93 µM, respectively.
Materials and Methods
Synthesis and chromatographic purification
Reagents were purchased from Sigma (Merck KGaA, Germany), and solvents were obtained from Macron Fine Chemicals (Avantor Performance Materials, USA). Reactions were monitored by TLC on Kieselgel 60F254 silica plates purchased from Merck (Merck, Germany), and characteristic spots of compounds were examined under UV illumination at 254 and 366 nm. Depending on the complexity of protoflavone product mixtures, chromatographic purification of components was carried out in one or two steps. For flash chromatography, a CombiFlash® Rf+ Lumen apparatus (TELEDYNE Isco, USA) was utilized that was equipped with ELS and diode array detectors. Components were separated on commercially available RediSep NP-silica flash columns (TELEDYNE Isco, USA) or manually filled polyamide columns. Mobile phase eluents consisted of mixtures of n-hexane -ethyl acetate or dichloromethane -methanol, modified according to the polarity of the analytes. To determine the composition of sample mixtures or to evaluate the purity of compounds, RP-HPLC analysis was performed on a Kinetex XB-C18 250 x 4.6 mm 5 µm or a Kinetex Biphenyl 250 x 4.6 mm 5 µm column (Phenomenex Inc., USA) at 1 ml/min flow rate, using a dual pump (PU-2080) Jasco HPLC instrument (Jasco Analytical Instruments, Japan) that was equipped with an MD-2010 Plus PDA detector to collect data in a detection range of 210-400 nm. For preparative purposes, an Armen Spot Prep II integrated HPLC purification system (Gilson, USA) with dual-wavelength detection was applied, operating at 230 and 300 nm. Preparative separations were performed on the corresponding Kinetex XB-C18 or Biphenyl 250 x 21.2 mm 5 µm columns with adequately chosen eluents of acetonitrile -water, and the flow rates were 15 ml/min.
Preparation of protoapigenone derivatives 2-8.
Protoapigenone and its 1'-O-alkyl ether analogs were synthesized following our previously described procedures [7] . Briefly, apigenin (1 mg/mL) was dissolved in a 9:1 v/v ratio mixture of acetonitrile and H2O or the alcohol to be coupled at C-1'. Under stirring, 2 equivalents of [bis(trifluoroacetoxy)iodo]benzene was added slowly to the solution and the reaction was left to develop for 1 hour at 80 °C. After completion, solvent was evaporated on a rotary evaporator and the residue was purified by flash chromatography allowing to obtain the corresponding protoflavones in pure form.
Preparation of tetrahydroprotoapigenone derivatives 9-14.
Selective hydrogenation of protoflavones was carried out based on our previous strategy [11] that relied on the application of an H-Cube ® continuous flow hydrogenation system (ThalesNano Inc., Hungary). The applied catalyst cartridge was a stainless-steel column (internal dimensions: 50 mm × 4.6 mm) containing approximately 200 mg of 5% Pd/C catalyst. The cartridge was inserted into an external thermostat (Jetstream 2 plus, Jasco, Japan) set to 25 °C. To provide continuous stream, a standard HPLC pump (Well-Chrom K-120, Knauer GmbH, Germany) was used. In each case, flow rate was set to 1 ml/min, and 40 bar pressure was applied in the system.
For each reaction, 20 mg of the corresponding protoflavone was dissolved / suspended in 20 mL of HPLC grade ethyl acetate and homogenized by sonication. To ensure reproducibility, between each reaction, the catalyst bed was washed with the solvent for 15 minutes. Following transformations, preparative RP-HPLC was utilized for chromatographic purification.
Preparation of tetradeuteroprotoapigenone derivatives 15-20.
Selective deuteration of the protoflavone B ring was performed similarly as described for hydrogenation with only slight modifications. In this case, approximately 400 mg of 5% Pd/BaSO4 was used as a catalyst, and the reservoir of the instrument was filled up with high purity heavy water (D2O). The obtained compounds 15-20 were purified by preparative RP-HPLC.
Preparation of protoflavone 4'-oxime derivatives 21-26.
An aliquot of 150 mg of compound 6, 7, or 8 was dissolved in methanol in a concentration of 2.5 mg/mL (50 mL). Following this, 3 equivalents of hydroxylamine hydrochloride were added to the solution, and the mixture was refluxed for 24 h at 70 °C. Silica gel (3-5 g) was added to the solution, and the solvent was evaporated to prepare for dry loading separation. The dried residue was applied to flash chromatography, and products were pre-purified by a gradient separation program of nhexane/ethyl acetate -100:0 (v/v) gradually increasing to 10:90 in 15 min. Following this, cis-and trans-isomeric racemate pairs (21 and 24, 22 and 25, 23 and 26, respectively) were separated by means of preparative RP-HPLC to obtain racemates 21-26.
Preparation of tetrahydroprotoflavone 4'-oxime derivatives 27-28.
An aliquot of 60 mg of tetrahydroprotoflavone 9 or 14 was dissolved in methanol in a concentration of 2.5 mg/mL (25 mL). 4 equivalents of hydroxylamine hydrochloride were added to the mixture, and the solution was stirred at 70 °C for 3 hours. Following this, solvent was evaporated on a rotary evaporator and brine (40 mL) was added to the residue. Extraction was performed with EtOAc (3x40 mL), and then the organic fractions were combined and dried over Na2SO4. Drying agent was removed through filtration, and the solution was evaporated under reduced pressure. Eventually, preparative RP-HPLC was applied to obtain oxime derivatives 27 and 28.
Structure elucidation
The compounds were characterized by NMR and MS techniques. NMR spectra were recorded at 25 °C on a Bruker Avance DRX 400 MHz (Bruker Co., USA) or on a Bruker Avance NEO 500 MHz spectrometer equipped with a Prodigy BBO 5 mm CryoProbe with the use of TMS as an internal standard. Typically, 5-10 mg of the corresponding protoflavone was dissolved in DMSO-d6 and transferred to NMR tubes for recording spectra. Data report and spectra analysis were carried out with MestReNova v6.0.2-5475 software (Mestrelab Research S.L., Spain). 1 H and 13 C NMR chemical shifts are listed below; residual hydrogen signals of the B-rings of deuterated compounds 15-20 are marked with an asterisk. Mass spectra were recorded on an API 2000 triple quadrupole tandem mass spectrometer (AB SCIEX, USA) equipped with ESI ion source that was used in the negative ionization mode. 
Immunoblot analysis of EBV Rta protein
P3HR1 cells were lysed in mRIPA buffer (50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 5 mM EDTA, 0.5 % Triton X-100, 0.5 % NP-40) [26, 27] . About 5% of the lysate was loaded to a gel and separated by electrophoresis in 10% SDS-PAGE. Proteins in the gel were electroblotted onto a polyvinylidene difluoride (PVDF) blotting membrane using a Hoefer transfer system. Rta was detected using mouse anti-Rta monoclonal antibody (Argene). α-Tubulin was detected using mouse anti-α-tubulin monoclonal antibody (Abcam). Primary antibodies were detected using horseradish peroxidaseconjugated secondary antibodies (Cell Signaling Technology) and then visualized using SuperSignal West Pico Chemiluminescent substrate (Pierce).
Cytotoxicity assay
P3HR1 cells (5 × 10 4 ) were seeded in wells of a 96-well plate and cultured for 24 h in 100 µL of RPMI 1640 medium containing protoapigenone or its analogs. Then 1% Triton X-100 was added as a negative control. Cytotoxicity was determined by Cell Proliferation Kit I (Roche). An aliquot of 10 µL of the MTT labeling reagent was added to each well and the plate was incubated for 4 h at 37°C. Then 100 µL solubilization solution was added to each well to dissolve insoluble formazan and was incubated overnight. Optical density was measured at 595 nm and 650 nm.
Conclusions
As a result of this work, the chemical space of non-cytotoxic protoflavonoids was significantly extended through the preparation of derivatives without the symmetric dienone moiety, such as saturated (hydrogenated or deuterated) B-ring and/or 4′-oxime containing protoflavones. Compound 9 was found to exert a weak antiretroviral activity that, due to the extremely low cytotoxicity of this compound, may still be of interest. Further, three compounds, the isopropyl-, butyl-and propargylether derivatives of protoapigenone were identified to act as potent anti-EBV agents at similar, medium-low nanomolar concentration range as their parent compound 2. Importantly, protoapigenone 1′-O-isopropyl ether demonstrated an order of magnitude lower cytotoxic effect as compared to protoapigenone, that makes compound 6 ca. 2.6-times more selective anti-EBV agent. Therefore, this compound can serve as a possible new lead for the development of safe and effective protoflavone derivatives against the lytic cycle of EBV.
Altogether, as a result of this work it may also be concluded that targeted chemical modifications of the protoflavone B-ring to decrease cytotoxicity represent a valid strategy towards the discovery of new bioactive compounds against pathologies other than cancer.
Supplementary Materials: 1 H and 13 C NMR spectra, and ESI-MS spectra of the novel compounds 10-13 and 15-28 are presented as Supplementary Figures S1-S36 (NMR) and Figures S37-S54 . Antiretroviral activity of compound 9 is presented as Figure S55 , and cytotoxic IC50 values for compounds 2, 6-14 and 21-28 on U373-CD4-CCR5 cells are presented as Table S1 .
